V Square Quantitative Management LLC Acquires 317 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

V Square Quantitative Management LLC raised its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 22.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,750 shares of the biotechnology company’s stock after acquiring an additional 317 shares during the quarter. V Square Quantitative Management LLC’s holdings in Axon Enterprise were worth $452,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. HB Wealth Management LLC lifted its position in Axon Enterprise by 3.9% during the fourth quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock valued at $294,000 after acquiring an additional 43 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in shares of Axon Enterprise by 1.1% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,997 shares of the biotechnology company’s stock worth $1,033,000 after purchasing an additional 43 shares in the last quarter. UMB Bank n.a. grew its stake in Axon Enterprise by 11.0% during the 4th quarter. UMB Bank n.a. now owns 444 shares of the biotechnology company’s stock worth $115,000 after buying an additional 44 shares during the last quarter. Lindbrook Capital LLC increased its position in Axon Enterprise by 43.3% during the 4th quarter. Lindbrook Capital LLC now owns 172 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 52 shares in the last quarter. Finally, NBC Securities Inc. raised its stake in Axon Enterprise by 1.4% in the fourth quarter. NBC Securities Inc. now owns 3,843 shares of the biotechnology company’s stock valued at $992,000 after buying an additional 53 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. StockNews.com downgraded shares of Axon Enterprise from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. JMP Securities reissued a “market outperform” rating and set a $375.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. JPMorgan Chase & Co. raised their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research note on Thursday, April 11th. TheStreet downgraded Axon Enterprise from a “b” rating to a “c+” rating in a research note on Tuesday, February 27th. Finally, Barclays raised their price objective on Axon Enterprise from $308.00 to $381.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $335.27.

Insider Buying and Selling

In other news, insider Jeffrey C. Kunins sold 43,668 shares of Axon Enterprise stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $309.94, for a total value of $13,534,459.92. Following the sale, the insider now owns 189,719 shares in the company, valued at $58,801,506.86. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Axon Enterprise news, Director Julie A. Cullivan sold 993 shares of the firm’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $281.72, for a total value of $279,747.96. Following the transaction, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jeffrey C. Kunins sold 43,668 shares of the company’s stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $309.94, for a total transaction of $13,534,459.92. Following the sale, the insider now directly owns 189,719 shares of the company’s stock, valued at approximately $58,801,506.86. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,447 shares of company stock valued at $27,684,677. 6.10% of the stock is owned by corporate insiders.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $292.33 on Monday. The company has a quick ratio of 2.55, a current ratio of 2.91 and a debt-to-equity ratio of 0.37. Axon Enterprise, Inc. has a 52 week low of $175.37 and a 52 week high of $329.87. The stock’s 50-day moving average price is $297.87 and its 200-day moving average price is $281.19. The stock has a market capitalization of $22.06 billion, a PE ratio of 85.48 and a beta of 0.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.95 by $0.20. The company had revenue of $460.74 million for the quarter, compared to analyst estimates of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. Axon Enterprise’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same period last year, the company earned $0.51 earnings per share. As a group, equities analysts expect that Axon Enterprise, Inc. will post 2.35 EPS for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.